CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
ALPHARETTA, Ga., Sept. 20, 2016 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced that Daniel H. White, Chief Executive Officer and President, will present at the 2016 Ladenburg Thalmann Healthcare Conference on Tuesday, September 27, 2016, at 10:30 a.m. EDT in at the Sofitel Hotel in New York, NY. Mr. White will provide a Clearside overview and business update.
The presentation will be webcast live and may be accessed by visiting Clearside’s website at http://ir.clearsidebio.com. A replay of the webcast will be available for 30 business days.
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a publicly-traded, late-stage clinical biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye using Clearside’s proprietary suprachoroidal space microinjector to reach diseased tissue through the suprachoroidal space. Clearside holds intellectual property protecting the delivery of drugs of any type through the suprachoroidal space to reach the back of the eye. Clearside has a portfolio of clinical and pre-clinical programs using drug administration through the suprachoroidal space to provide a route of access to treat diseases of the back-of-the-eye such as retinal vein occlusion (RVO), uveitis, neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Clearside is currently enrolling patients in a Phase 3 clinical trial (PEACHTREE) for the treatment of patients with macular edema associated with non-infectious uveitis and has initiated IND-enabling studies for the treatment of wet AMD. Visit www.clearsidebio.com for more information.
Contacts Company: Charles Deignan Chief Financial Officer 678-270-4005 [email protected] Investors: Matthew Beck The Trout Group 646-378-2933 [email protected]
